Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Cox models survival analysis based on breast cancer treatments.

Abadi A, Yavari P, Dehghani-Arani M, Alavi-Majd H, Ghasemi E, Amanpour F, Bajdik C.

Iran J Cancer Prev. 2014 Summer;7(3):124-9.

2.

Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

Davidson A, Chia S, Olson R, Nichol A, Speers C, Coldman AJ, Bajdik C, Woods R, Tyldesley S.

CMAJ Open. 2013 Nov 7;1(4):E134-41. doi: 10.9778/cmajo.20130017. eCollection 2013 Oct.

3.

Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre.

Lam E, Strugnell SS, Bajdik C, Holmes D, Wiseman SM.

Can J Surg. 2013 Dec;56(6):385-92.

4.

Synoptic pathology reporting for thyroid cancer: a review and institutional experience.

Lam E, Vy N, Bajdik C, Strugnell SS, Walker B, Wiseman SM.

Expert Rev Anticancer Ther. 2013 Sep;13(9):1073-9. doi: 10.1586/14737140.2013.825435. Review.

PMID:
24053206
5.

Influence of fluorescence on screening decisions for oral mucosal lesions in community dental practices.

Laronde DM, Williams PM, Hislop TG, Poh C, Ng S, Bajdik C, Zhang L, MacAulay C, Rosin MP.

J Oral Pathol Med. 2014 Jan;43(1):7-13. doi: 10.1111/jop.12090. Epub 2013 Jun 10.

6.

Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.

Bashash M, Shah A, Hislop G, Treml M, Bretherick K, Janoo-Gilani R, Leach S, Le N, Bajdik C, Brooks-Wilson A.

PLoS One. 2013;8(3):e59157. doi: 10.1371/journal.pone.0059157. Epub 2013 Mar 19.

7.

Gender- and ethnicity-specific survival trends of oral cavity and oropharyngeal cancers in British Columbia.

Auluck A, Hislop G, Bajdik C, Hay J, Bottorff JL, Zhang L, Rosin MP.

Cancer Causes Control. 2012 Dec;23(12):1899-909. doi: 10.1007/s10552-012-0065-0. Epub 2012 Sep 28.

PMID:
23053792
9.

Applying conventional and saturated generalized gamma distributions in parametric survival analysis of breast cancer.

Yavari P, Abadi A, Amanpour F, Bajdik C.

Asian Pac J Cancer Prev. 2012;13(5):1829-31.

10.

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.

Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD.

Br J Cancer. 2012 Aug 21;107(5):800-7. doi: 10.1038/bjc.2012.338. Epub 2012 Jul 31.

11.

Cancer risk in multiple sclerosis: findings from British Columbia, Canada.

Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H.

Brain. 2012 Oct;135(Pt 10):2973-9. doi: 10.1093/brain/aws148. Epub 2012 Jun 21.

PMID:
22730559
12.

Demographic and tumor characteristics of patients diagnosed with nonmelanoma skin cancer: 13-year retrospective study.

Mistry N, Abanto Z, Bajdik C, Rivers JK.

J Cutan Med Surg. 2012 Jan-Feb;16(1):32-8.

PMID:
22417993
13.

Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomes.

Olson RA, Nichol A, Caron NR, Olivotto IA, Speers C, Chia S, Davidson A, Coldman A, Bajdik C, Tyldesley S.

Can J Public Health. 2012 Jan-Feb;103(1):46-52.

PMID:
22338328
14.

Adherence to dietary recommendations and risk of esophageal squamous cell carcinoma: a case-control study in Iran.

Jessri M, Rashidkhani B, Hajizadeh B, Jessri M, Kreiger N, Bajdik CD.

Ann Nutr Metab. 2011;59(2-4):166-75. doi: 10.1159/000334334. Epub 2011 Dec 2.

PMID:
22142938
15.

A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes.

Nichol AM, Yerushalmi R, Tyldesley S, Lesperance M, Bajdik CD, Speers C, Gelmon KA, Olivotto IA.

J Clin Oncol. 2011 Dec 20;29(36):4763-8. doi: 10.1200/JCO.2011.35.0165. Epub 2011 Nov 21.

PMID:
22105824
16.

The prognostic effect of ethnicity for gastric and esophageal cancer: the population-based experience in British Columbia, Canada.

Bashash M, Hislop TG, Shah AM, Le N, Brooks-Wilson A, Bajdik CD.

BMC Cancer. 2011 May 9;11:164. doi: 10.1186/1471-2407-11-164.

17.

A population-based validation of the prognostic model PREDICT for early breast cancer.

Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, Caldas C, Pharoah PD.

Eur J Surg Oncol. 2011 May;37(5):411-7. doi: 10.1016/j.ejso.2011.02.001. Epub 2011 Mar 2.

PMID:
21371853
18.

Ultraviolet radiation.

Gallagher RP, Lee TK, Bajdik CD, Borugian M.

Chronic Dis Can. 2010;29 Suppl 1:51-68. Review.

PMID:
21199599
19.
20.

Comparison of two diverse populations, British Columbia, Canada, and Ardabil, Iran, indicates several variables associated with gastric and esophageal cancer survival.

Bashash M, Yavari P, Hislop TG, Shah A, Sadjadi A, Babaei M, Le N, Brooks-Wilson A, Malekzadeh R, Bajdik C.

J Gastrointest Cancer. 2011 Mar;42(1):40-5. doi: 10.1007/s12029-010-9228-y.

21.

Hepatitis B ESL education for Asian immigrants.

Taylor VM, Gregory Hislop T, Bajdik C, Teh C, Lam W, Acorda E, Li L, Yasui Y.

J Community Health. 2011 Feb;36(1):35-41. doi: 10.1007/s10900-010-9279-9.

22.

Breast cancer treatment and ethnicity in British Columbia, Canada.

Yavari P, Barroetavena MC, Hislop TG, Bajdik CD.

BMC Cancer. 2010 Apr 21;10:154. doi: 10.1186/1471-2407-10-154.

23.
24.

Evaluation of a hepatitis B educational ESL curriculum for Chinese immigrants.

Taylor VM, Teh C, Lam W, Acorda E, Li L, Coronado G, Yasui Y, Bajdik C, Hislop G.

Can J Public Health. 2009 Nov-Dec;100(6):463-6.

25.

The identification of Lynch syndrome in British Columbia.

Cremin CM, Armstrong L, Gill S, Huntsman D, Bajdik C.

Can J Gastroenterol. 2009 Nov;23(11):761-7.

26.

Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada.

Sadjadi A, Hislop TG, Bajdik C, Bashash M, Ghorbani A, Nouraie M, Babaei M, Malekzadeh R, Yavari P.

BMC Cancer. 2009 Oct 28;9:381. doi: 10.1186/1471-2407-9-381.

27.

A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.

Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, Speers C, Hassell P, O'Reilly SE, Allan S, Shenkier TN.

Clin Breast Cancer. 2009 Aug;9(3):166-72. doi: 10.3816/CBC.2009.n.027.

PMID:
19661040
28.

Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer.

Monzon JG, Cremin C, Armstrong L, Nuk J, Young S, Horsman DE, Garbutt K, Bajdik CD, Gill S.

Int J Cancer. 2010 Feb 15;126(4):930-9. doi: 10.1002/ijc.24808.

29.

Hepatitis B testing and vaccination in immigrants attending English as a second language classes in British Columbia, Canada.

Hislop TG, Bajdik CD, Teh C, Lam W, Tu SP, Yasui Y, Bastani R, Taylor VM.

Asian Pac J Cancer Prev. 2009;10(6):997-1002.

30.

Agreement between birthplace and self-reported ethnicity in a population-based mammography service.

Bajdik CD, Barroetavena MC, Saroa SR, Hislop TG.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):511-4.

31.

Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.

Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK.

Clin Breast Cancer. 2008 Jun;8(3):249-56. doi: 10.3816/CBC.2008.n.028.

PMID:
18650155
32.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

33.

Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999.

Bashash M, Shah A, Hislop G, Brooks-Wilson A, Le N, Bajdik C.

Can J Gastroenterol. 2008 Feb;22(2):143-8.

34.

Predicting the performance of a genetic testing service for cancer susceptibility.

Bajdik CD, Sung S, Spinelli JJ, Huntsman D, Gallinger S, Horsman D, Gallagher RP.

Genet Test. 2007 Winter;11(4):381-6. doi: 10.1089/gte.2007.0031.

PMID:
18294053
35.

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.

Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.

Cancer. 2008 Apr 1;112(7):1437-44. doi: 10.1002/cncr.23320.

36.

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA.

Breast Cancer Res. 2008;10(1):R6. doi: 10.1186/bcr1847. Epub 2008 Jan 14.

37.

Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada.

Hislop GT, Bajdik CD, Regier MD, Barroetavena MC.

Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):209-14.

38.

Cancer incidence in Indians from three areas: Delhi and Mumbai, India, and British Columbia, Canada.

Hislop TG, Bajdik CD, Saroa SR, Yeole BB, Barroetavena MC.

J Immigr Minor Health. 2007 Jul;9(3):221-7.

PMID:
17245655
39.

Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM.

J Clin Oncol. 2006 Dec 20;24(36):5637-44. Epub 2006 Nov 20.

PMID:
17116944
40.

Identifying related cancer types based on their incidence among people with multiple cancers.

Bajdik CD, Abanto ZU, Spinelli JJ, Brooks-Wilson A, Gallagher RP.

Emerg Themes Epidemiol. 2006 Nov 8;3:17.

41.

Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.

Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K.

Clin Breast Cancer. 2006 Aug;7(3):254-61.

PMID:
16942643
42.

Physical and emotional health effects and social consequences after participation in a low-fat, high-carbohydrate dietary trial for more than 5 years.

Hislop TG, Bajdik CD, Balneaves LG, Holmes A, Chan S, Wu E, Abanto ZU, Butler AL.

J Clin Oncol. 2006 May 20;24(15):2311-7.

PMID:
16710029
43.

Comparison of cancer incidence in Iran and Iranian immigrants to British Columbia, Canada.

Yavari P, Hislop TG, Bajdik C, Sadjadi A, Nouraie M, Babai M, Malekzadeh R.

Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):86-90.

44.

MDM2 protein expression is a negative prognostic marker in breast carcinoma.

Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB.

Mod Pathol. 2006 Jan;19(1):69-74.

45.

Do work-related breast cancer risks in pre-menopausal women depend on family history?

Bajdik CD, Fang R, Band PR, Le N, Gallagher RP.

Chronic Dis Can. 2004 Summer-Fall;25(3-4):147-51.

PMID:
15841855
46.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA.

J Clin Oncol. 2005 Apr 20;23(12):2716-25.

PMID:
15837986
47.
48.

Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer.

Bajdik CD, Raboud JM, McGillivray BC, Schechter MT, Gallagher RP.

Genet Test. 2004 Fall;8(3):229-34.

PMID:
15727244
49.

Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin.

Kennedy C, Bajdik CD, Willemze R, Bouwes Bavinck JN.

Br J Dermatol. 2005 Jan;152(1):194-7. No abstract available.

PMID:
15656837
50.

Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.

Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51.

Supplemental Content

Loading ...
Support Center